About
Bioxis Pharmaceuticals is a dynamic company focused on the discovery, development, production, and commercialization of innovative regenerative medical products, particularly in dermatology and medical aesthetics. The company is dedicated to creating advanced medical devices and biomaterial scaffolds using patented technology aimed at tissue regeneration and improving patient outcomes. Bioxis is known for its development of MTI12, the first Monophasic Tissular Inductor, which utilizes proprietary chitosan technology to enhance dermal filler treatments. Additionally, the company offers CYTOSIAL, a line of crosslinked hyaluronic acid-based dermal fillers that has gained traction in Europe and Asia since its launch in 2017. Bioxis maintains a fully integrated ecosystem that encompasses research and development, manufacturing, and distribution, ensuring high quality and innovation in its products. Targeting medical professionals in dermatology and aesthetics, Bioxis Pharmaceuticals aims to enhance the quality of care for patients seeking aesthetic treatments and tissue regeneration therapies. The company's commitment to advancing medical aesthetics is evident in its proprietary technologies and comprehensive service offerings.
Technologies
Keywords
Company Information
-
Employees 23
-
Founded 2010
-
Total Funding $2804000
Location
317 Avenue Jean Jaures, Lyon, Auvergne-Rhone-Alpes, France, 69007
